Human medicines European public assessment report (EPAR): Ekterly, sebetralstat, Date of authorisation: 17/09/2025, Status: Authorised
EMEA-001073-PIP02-14
Opinion/decision on a Paediatric investigation plan (PIP): Gazyvaro, Obinutuzumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0502/2022
PSUSA/00010130/202502
Human medicines European public assessment report (EPAR): Bemrist Breezhaler, indacaterol,mometasone, Date of authorisation: 30/05/2020, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Selincro, nalmefene, Date of authorisation: 24/02/2013, Revision: 15, Status: Authorised
Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 39, Status: Authorised
Minutes of the CHMP written procedure 18-21 August 2025
SPOR and XEVMPD status update webinar, Broadcast, from 8 October 2025, 10:00 (CEST) to 8 October 2025, 12:30 (CEST)
Agenda of the CAT meeting 8-9 October 2025